Company profiles, stock analysis, market trends, and investment insights
18 articles
CRISPR Therapeutics (CRSP) made history with the first approved CRISPR therapy. Here's their full pipeline, financials, and what's next in 2026.
From record-fast oral GLP-1 approvals and Medicare coverage to compounding crackdowns and RFK Jr.'s peptide reclassification push — a comprehensive look at every major FDA and US healthcare action on peptides in 2025-2026, which companies benefit, and what it means for patients and investors.
A 2026 investor guide to GLP-1 stocks: Novo Nordisk vs Eli Lilly, pipeline, market cap, risks, and the obesity drug challengers to watch.
Why peptide manufacturing became the GLP-1 bottleneck. A 2026 investor guide to Bachem, PolyPeptide, Lonza, and the peptide CDMO pick-and-shovel trade.
How to invest in the peptide therapeutics boom via ETFs and funds. Obesity-themed, broad biotech, and pharma mega-cap options compared for 2026.
A comprehensive investor's guide to gene editing — from genomics ETFs (ARKG, GNOM, IDNA) and longevity venture funds to publicly traded companies across 12 countries and the indexes tracking this sector.
Life Biosciences launched the first-ever human trial of epigenetic reprogramming in January 2026 — an AAV gene therapy that uses three Yamanaka factors to reverse aging in the eye. Here's the full story of the company, its science, and what it means for the future of longevity medicine.
From billion-dollar reprogramming ventures to canine longevity drugs, here are the biotech companies leading the charge against aging in 2026.
A look at the publicly traded gene editing companies best positioned for 2026, from the first approved CRISPR therapy to next-generation platforms targeting cardiovascular disease and cancer.
CRISPR Therapeutics, Intellia, Beam, and more: the gene editing companies leading in 2026. Pipelines, approved therapies, and which stocks investors are watching.
Three companies, three different gene editing technologies, three different investment theses. Here's how Intellia (CRISPR), Beam (base editing), and Prime Medicine (prime editing) compare as investments in 2026.
How artificial intelligence is transforming gene editing, from designing better guide RNAs to predicting protein structures and engineering novel gene editors.
Demis Hassabis built DeepMind and created AlphaFold, the AI that solved protein structure prediction — earning a Nobel Prize and transforming drug discovery and gene editing.
Jason Kelly co-founded Ginkgo Bioworks to be the 'organism company' — building the world's largest platform for programming cells and engineering biology at industrial scale.
Editas Medicine was the first CRISPR company, co-founded by Feng Zhang with Broad Institute patents. But while competitors won FDA approvals, Editas struggled. Here's what happened.
Eli Lilly acquired Verve Therapeutics for $1.3 billion in July 2025 — the biggest signal yet that big pharma believes in one-time genetic cures for chronic diseases.
The gene editing market is projected to grow from $8.9 billion in 2024 to $45 billion by 2034 — a 17% CAGR. Here's where the growth is coming from and which segments will dominate.
The battle over CRISPR patents between the Broad Institute and UC Berkeley is one of the most consequential IP fights in biotech history. Here's who won, what it means, and why it matters.